AnaptysBio Inc logo

AnaptysBio Inc

2
1
NAS:ANAB (USA)  
$ 30.10 -0.22 (-0.73%) 10:08 PM EST
At Loss
P/B:
17.21
Market Cap:
$ 822.29M
Enterprise V:
$ 485.01M
Volume:
334.55K
Avg Vol (2M):
315.24K
Trade In:
Volume:
334.55K
At Loss
Avg Vol (2M):
315.24K

Business Description

Description
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Name Current Vs Industry Vs History
Cash-To-Debt 20.4
Equity-to-Asset 0.12
Debt-to-Equity 0.36
Debt-to-EBITDA -0.12
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.99
Distress
Grey
Safe
Beneish M-Score -1.04
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 88.8
9-Day RSI 82.84
14-Day RSI 76.32
6-1 Month Momentum % 4.06
12-1 Month Momentum % 17.39

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 11.53
Quick Ratio 11.53
Cash Ratio 10.98
Days Sales Outstanding 69.67

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 0.9
Shareholder Yield % 1.47

Financials (Next Earnings Date:2024-08-07 Est.)

ANAB's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ANAB

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

AnaptysBio Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 22.962
EPS (TTM) ($) -6.14
Beta 0.05
Volatility % 59.98
14-Day RSI 76.32
14-Day ATR ($) 1.300734
20-Day SMA ($) 25.016
12-1 Month Momentum % 17.39
52-Week Range ($) 13.36 - 31.52
Shares Outstanding (Mil) 27.32

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

AnaptysBio Inc Filings

Filing Date Document Date Form
No Filing Data

AnaptysBio Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

AnaptysBio Inc Frequently Asked Questions

What is AnaptysBio Inc(ANAB)'s stock price today?
The current price of ANAB is $30.10. The 52 week high of ANAB is $31.52 and 52 week low is $13.36.
When is next earnings date of AnaptysBio Inc(ANAB)?
The next earnings date of AnaptysBio Inc(ANAB) is 2024-08-07 Est..
Does AnaptysBio Inc(ANAB) pay dividends? If so, how much?
AnaptysBio Inc(ANAB) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1